Madrigal Pharmaceuticals Inc (NASDAQ:MDGL)

285.35
Delayed Data
As of Jun 21
 -16.67 / -5.52%
Today’s Change
13.61
Today|||52-Week Range
325.98
+210.87%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$1.8B

Company Description

Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.

Contact Information

Madrigal Pharmaceuticals, Inc.
200 Barr Harbor Drive
West Conshohocken Pennsylvania 19428
P:(484) 380-9263
Investor Relations:

Employees

Shareholders

Individual stakeholders48.64%
Other institutional31.18%
Mutual fund holders13.00%

Top Executives

Paul A. FriedmanChairman, President & Chief Executive Officer
Marc R. SchneebaumCFO, Principal Accounting Officer & Senior VP
Rebecca A. TaubDirector & Chief Medical Officer